Citadel Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $12.3M | Sell |
37,200
-52,900
| -59% | -$18M | ﹤0.01% | 2961 |
|
|
2025
Q4 | $35.8M | Buy |
90,100
+19,300
| +27% | +$8.54M | 0.01% | 1739 |
|
|
2025
Q3 | $32.3M | Buy |
70,800
+31,500
| +80% | +$12.8M | ﹤0.01% | 1799 |
|
|
2025
Q2 | $12.8M | Sell |
39,300
-12,300
| -24% | -$3.4M | ﹤0.01% | 2701 |
|
|
2025
Q1 | $13.9M | Sell |
51,600
-6,800
| -12% | -$1.75M | ﹤0.01% | 2452 |
|
|
2024
Q4 | $13.7M | Sell |
58,400
-76,800
| -57% | -$20.2M | ﹤0.01% | 2582 |
|
|
2024
Q3 | $37.2M | Sell |
135,200
-7,100
| -5% | -$1.85M | 0.01% | 1488 |
|
|
2024
Q2 | $34.6M | Buy |
142,300
+4,400
| +3% | +$695K | 0.01% | 1481 |
|
|
2024
Q1 | $20.6M | Buy |
137,900
+26,800
| +24% | +$4.47M | ﹤0.01% | 2028 |
|
|
2023
Q4 | $21.3M | Buy |
111,100
+16,400
| +17% | +$2.79M | ﹤0.01% | 1952 |
|
|
2023
Q3 | $16.8M | Sell |
94,700
-12,500
| -12% | -$2.38M | ﹤0.01% | 2060 |
|
|
2023
Q2 | $20.4M | Sell |
107,200
-42,300
| -28% | -$8.39M | ﹤0.01% | 1865 |
|
|
2023
Q1 | $29.9M | Buy |
149,500
+35,500
| +31% | +$7.46M | 0.01% | 1537 |
|
|
2022
Q4 | $27.1M | Sell |
114,000
-8,700
| -7% | -$1.86M | 0.01% | 1648 |
|
|
2022
Q3 | $24.6M | Sell |
122,700
-59,600
| -33% | -$11.4M | 0.01% | 1673 |
|
|
2022
Q2 | $26.6M | Buy |
182,300
+88,300
| +94% | +$12.5M | 0.01% | 1566 |
|
|
2022
Q1 | $15.3M | Sell |
94,000
-26,500
| -22% | -$4.04M | ﹤0.01% | 2329 |
|
|
2021
Q4 | $20.4M | Buy |
120,500
+47,100
| +64% | +$8.75M | ﹤0.01% | 1991 |
|
|
2021
Q3 | $13.9M | Sell |
73,400
-12,600
| -15% | -$2.36M | ﹤0.01% | 2548 |
|
|
2021
Q2 | $14.6M | Buy |
86,000
+59,800
| +228% | +$8.76M | ﹤0.01% | 2514 |
|
|
2021
Q1 | $3.7M | Sell |
26,200
-31,800
| -55% | -$4.79M | ﹤0.01% | 4951 |
|
|
2020
Q4 | $7.54M | Sell |
58,000
-7,900
| -12% | -$1.05M | ﹤0.01% | 3034 |
|
|
2020
Q3 | $9.6M | Sell |
65,900
-2,600
| -4% | -$369K | ﹤0.01% | 2338 |
|
|
2020
Q2 | $10.1M | Buy |
68,500
+6,100
| +10% | +$822K | ﹤0.01% | 2201 |
|
|
2020
Q1 | $6.79M | Buy |
62,400
+11,600
| +23% | +$1.34M | ﹤0.01% | 2321 |
|
|
2019
Q4 | $5.85M | Buy |
50,800
+17,300
| +52% | +$1.72M | ﹤0.01% | 2895 |
|
|
2019
Q3 | $2.69M | Sell |
33,500
-27,900
| -45% | -$2.21M | ﹤0.01% | 4014 |
|
|
2019
Q2 | $4.46M | Buy |
61,400
+3,600
| +6% | +$276K | ﹤0.01% | 3265 |
|
|
2019
Q1 | $5.4M | Sell |
57,800
-33,200
| -36% | -$2.78M | ﹤0.01% | 2891 |
|
|
2018
Q4 | $6.63M | Buy |
91,000
+16,900
| +23% | +$1.3M | ﹤0.01% | 2401 |
|
|
2018
Q3 | $6.49M | Buy |
74,100
+10,200
| +16% | +$1.03M | ﹤0.01% | 2650 |
|
|
2018
Q2 | $6.29M | Buy |
63,900
+32,100
| +101% | +$3.18M | ﹤0.01% | 2466 |
|
|
2018
Q1 | $3.79M | Sell |
31,800
-31,100
| -49% | -$4.01M | ﹤0.01% | 2812 |
|
|
2017
Q4 | $7.99M | Sell |
62,900
-29,400
| -32% | -$3.69M | ﹤0.01% | 1952 |
|
|
2017
Q3 | $10.8M | Buy |
92,300
+74,200
| +410% | +$6.33M | 0.01% | 1530 |
|
|
2017
Q2 | $1.44M | Sell |
18,100
-2,400
| -12% | -$153K | ﹤0.01% | 3588 |
|
|
2017
Q1 | $1.05M | Buy |
20,500
+5,800
| +39% | +$268K | ﹤0.01% | 3926 |
|
|
2016
Q4 | $550K | Buy |
14,700
+5,500
| +60% | +$230K | ﹤0.01% | 4751 |
|
|
2016
Q3 | $624K | Sell |
9,200
-7,400
| -45% | -$522K | ﹤0.01% | 4509 |
|
|
2016
Q2 | $921K | Buy |
16,600
+1,400
| +9% | +$88.2K | ﹤0.01% | 3660 |
|
|
2016
Q1 | $954K | Buy |
15,200
+300
| +2% | +$19.9K | ﹤0.01% | 3552 |
|
|
2015
Q4 | $1.4M | Sell |
14,900
-19,800
| -57% | -$1.84M | ﹤0.01% | 3176 |
|
|
2015
Q3 | $2.79M | Sell |
34,700
-19,300
| -36% | -$2.14M | ﹤0.01% | 2549 |
|
|
2015
Q2 | $6.47M | Buy |
54,000
+26,300
| +95% | +$3.14M | 0.01% | 1824 |
|
|
2015
Q1 | $2.89M | Buy |
27,700
+13,000
| +88% | +$1.32M | ﹤0.01% | 2633 |
|
|
2014
Q4 | $1.43M | Buy |
14,700
+3,800
| +35% | +$352K | ﹤0.01% | 3315 |
|
|
2014
Q3 | $851K | Sell |
10,900
-1,300
| -11% | -$83.9K | ﹤0.01% | 3907 |
|
|
2014
Q2 | $771K | Sell |
12,200
-5,700
| -32% | -$339K | ﹤0.01% | 3829 |
|
|
2014
Q1 | $1.2M | Buy |
17,900
+7,700
| +75% | +$596K | ﹤0.01% | 3208 |
|
|
2013
Q4 | $656K | Sell |
10,200
-5,300
| -34% | -$316K | ﹤0.01% | 3692 |
|
|
2013
Q3 | $992K | Sell |
15,500
-6,300
| -29% | -$314K | ﹤0.01% | 3131 |
|
|
2013
Q2 | $676K | Buy |
+21,800
| New | +$580K | ﹤0.01% | 3546 |
|
Other funds holding ALNY
VPM
VCM
Citadel Advisors's ALNY Position: Q1 2026 in Review
Citadel Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 39% in Q1 2026, selling an estimated $5.12M and leaving 23,415 shares worth $7.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3628.
Citadel Advisors first reported a position in ALNY in Q2 2013 and has held it in 45 quarters since. The position peaked at $196M in Q2 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Citadel Advisors held 23,415 shares of Alnylam Pharmaceuticals worth $7.75M as of Q1 2026.
- Citadel Advisors sold 15,044 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $5.12M.
- Alnylam Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3628 holding.
- Citadel Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
- Citadel Advisors's Alnylam Pharmaceuticals position peaked at $196M in Q2 2025.
- 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.